ARRAY BIOPHARMA INC.
BOULDER, CO

Array BioPharma – Clinical Operations, Cambridge, MA Array BioPharma – Clinical Operations, Morrisville, NC Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics). We are building a fully integrated, commercial-stage biopharmaceutical company that discovers, develops and markets safe and effective small molecule drugs to treat patients afflicted with cancer. We intend to accomplish this through the following strategies: Ron Squarer has served as Chief Executive Officer and a member of the Array Board of Directors since April 2012. Mr. Squarer has extensive commercial, development and executive leadership expertise from a greater than two decade career in the biopharmaceutical industry. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as Senior Vice President, Chief Commercial Officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007 for over $2 billion. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer currently serves as a member of the Board of Directors of Retrophin, Inc. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor’s degree in biochemistry from the University of California, Berkeley. Mr. Haddock joined Array as Chief Financial Officer in July 2016. He has more than 15 years of financial and operational experience in the biopharmaceutical industry. Mr. Haddock held leadership positions of increasing responsibility at Bristol-Myers Squibb, a global pharmaceutical company with a strong focus on immuno-oncology therapies. During that time, he served in variety of accounting, planning, commercial, analytical and business development capacities for high-growth business units, including Head of Finance for the Worldwide Commercialization and Medical teams. Mr. Haddock also served as Executive Director for the U.S. Pharmaceutical unit, where he focused on designing and implementing a completely new business model and operations to capitalize on future product portfolio changes and market developments. Mr. Haddock most recently served as Chief Financial Officer and Chief Operating Officer of BERG Health, an oncology focused research, diagnostics and development company, where he oversaw the implementation of financial and operational processes, procedures and policies to transform and scale the company’s practices as it planned for growth and corporate evolution. Mr. Haddock earned his undergraduate degree in accountancy from Illinois State University and is a Certified Management Accountant. He holds an MBA from Washington University in St. Louis where he completed the Executive Program. Mr. Oltmans has served as Executive Vice President, General Counsel and Secretary since August 2017. Prior to joining Array, Mr. Oltmans served as Corporate Vice President and General Counsel, North America, at Novo Nordisk, Inc., a fully integrated global healthcare company, where he was responsible for strategy and initiatives in the areas of law, including intellectual property and litigation, and public affairs for the company’s substantial business in North America. Prior to Novo Nordisk, Mr. Oltmans spent 13 years at Eli Lilly and Company in a variety of legal roles, including litigation, FDA regulatory and international law. Mr. Oltmans earned his undergraduate degree in political science at the University of Nebraska and his Juris Degree at the University of Nebraska College of Law. Dr. Victor Sandor has served as Chief Medical Officer since September 2014. Dr. Sandor has more than a decade of experience in the pharmaceutical and biotechnology industries. Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation. In this role, he was instrumental in the development, approval and commercialization of Jakafi® (ruxolitinib), the first JAK inhibitor, while leading clinical development, clinical operations, medical affairs and biostatistics across the entire portfolio, including responsibility for several novel mechanisms including PI3K, c-Met and IDO1 inhibitors. Prior to Incyte, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec. He previously held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex® (anastrozole) for adjuvant use, the development of Faslodex® (fulvestrant injection), and the development of several early stage programs through proof of concept. Dr. Sandor received his MD CM from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland. Andrew Robbins has served as Chief Operating Officer since March 2015 and previously served as Senior Vice President of Commercial Operations since July 2012. Mr. Robbins has extensive commercial, development and strategic leadership expertise from a 17-year career in the pharmaceutical industry, with a specific focus on oncology/hematology products. Most recently he was at Hospira, Inc. where he served as General Manager/Vice President of the U.S. Alternate Site business unit, focused on the sales of pharmaceuticals and medical devices to outpatient oncology, surgery, pain and dialysis customers. In this role, he led a team of approximately 100 employees, including a national sales force, to deliver over $400 million in annual revenue. Prior to this, he was Vice President of Corporate Development and was responsible for global branded pharmaceutical marketing and business development, research and development portfolio prioritization, global strategy and corporate venture investing. During his tenure, he designed and executed a strategy to build a late-stage hematology/oncology and acute pain pipeline via licensing and acquisition. Mr. Robbins also served on the Board of Directors for three venture-backed healthcare companies, two of which were focused on innovative hematology/oncology products. Before Hospira, Mr. Robbins was a commercial leader within Pfizer’s oncology unit, responsible for shepherding a portfolio of 12 preclinical and clinical stage products through development using a “fast-to-patient” approach. Several of these products, including Sutent